Found: 7
Select item for more details and to access through your institution.
Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Treatment With Tafamidis Slows Disease Progression in Early-Stage Transthyretin Cardiomyopathy.
- Published in:
- Clinical Medicine Insights: Cardiology, 2017, v. 11, p. 1, doi. 10.1177/1179546817730322
- By:
- Publication type:
- Article
Effect of long‐term tafamidis treatment on health‐related quality of life in patients with transthyretin amyloid cardiomyopathy.
- Published in:
- European Journal of Heart Failure, 2024, v. 26, n. 3, p. 612, doi. 10.1002/ejhf.3190
- By:
- Publication type:
- Article
Reply to 'Effects of tafamidis on heart failure hospitalization: The tale of the dog that did not bark'.
- Published in:
- European Journal of Heart Failure, 2024, v. 26, n. 2, p. 526, doi. 10.1002/ejhf.3042
- By:
- Publication type:
- Article
Improved long‐term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms.
- Published in:
- European Journal of Heart Failure, 2023, v. 25, n. 11, p. 2060, doi. 10.1002/ejhf.2974
- By:
- Publication type:
- Article
Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study.
- Published in:
- European Journal of Heart Failure, 2021, v. 23, n. 2, p. 277, doi. 10.1002/ejhf.2027
- By:
- Publication type:
- Article
Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACT.
- Published in:
- ESC Heart Failure, 2021, v. 8, n. 5, p. 3875, doi. 10.1002/ehf2.13541
- By:
- Publication type:
- Article